Results 31 to 40 of about 25,757 (158)
Revista Brasileira de Hematologia e Hemoterapia, 2015 Myelodysplastic syndromes represent a group of heterogeneous hematopoietic neoplasms derived from an abnormal multipotent progenitor cell, characterized by a hyperproliferative bone marrow, dysplasia of the cellular hemopoietic elements and ineffective ...
Emmanouil Petrou +6 more
doaj +1 more source
Haematologica, 2017 Accumulating evidence implicates innate immune activation in the pathobiology of myelodysplastic syndromes. A key myeloid-related inflammatory protein, S100A9, serves as a Toll-like receptor ligand regulating tumor necrosis factor-α and interleukin-1β ...
Thomas Cluzeau +11 more
doaj +1 more source
Therapy-related myeloid neoplasms following treatment with radioiodine
Haematologica, 2012 Background Few data are available on therapy-related myelodysplastic syndromes and acute myeloid leukemia developing after radioiodine treatment.Design and Methods We retrospectively analyzed 39 patients with myeloid neoplasms following radioiodine ...
Thomas Schroeder +17 more
doaj +1 more source
The revolution of myelodysplastic syndromes [PDF]
Therapeutic Advances in Hematology, 2011 Myelodysplastic syndromes (MDS) are clonal disorders of the hematopoietic system with resultant cytopenias and shortened survival. Better recognition of MDS and an aging population, some of whom have been treated with chemotherapy and radiation therapy for other cancers, is largely responsible for the growing incidence of this malignancy, which is ...
Mikkael A, Sekeres, Nelli, Bejanyan
openaire +2 more sources
Haematologica, 2012 Background There are limited reports of thrombosis among myelodysplastic syndrome patients exposed to erythropoiesis stimulating agents. It is not clear whether erythropoiesis stimulating agents are associated with an increased risk of thrombosis in ...
Sheila Weiss Smith +6 more
doaj +1 more source
Clinical and genetic predictors of prognosis in myelodysplastic syndromes
Haematologica, 2014 Myelodysplastic syndromes are a collection of clonal hematopoietic disorders with a wide range of clinical manifestations and eventual outcomes. Accurate prediction of a patient’s prognosis is useful to define the risk posed by the disease and which ...
Rafael Bejar
doaj +1 more source
Haematologica, 2013 Interstitial deletion of chromosome 5q is the most common chromosomal abnormality in myelodysplastic syndromes. The catalogue of genes involved in the molecular pathogenesis of myelodysplastic syndromes is rapidly expanding and next-generation sequencing
Marta Fernandez-Mercado +11 more
doaj +1 more source
Haematologica, 2018 Mesenchymal stromal cells are involved in the pathogenesis of myelodysplastic syndromes and acute myeloid leukemia, but the underlying mechanisms are incompletely understood.
Stefanie Geyh +11 more
doaj +1 more source
Emerging Therapies for the Myelodysplastic Syndromes
Clinical Hematology International, 2019 Despite considerable advances in our understanding of the molecular and epigenetic underpinnings of the myelodysplastic syndromes (MDS), this diverse group of myeloid neoplasms remains a significant clinical challenge.
Jonathan Canaani
doaj +1 more source
Myelodysplastic syndromes and overlap syndromes
BLOOD RESEARCH, 2021 Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematological neoplasms characterized by ineffective hematopoiesis, morphologic dysplasia, and cytopenia. MDS overlap syndromes include various disorders, such as myelodysplastic/myeloproliferative neoplasms and hypoplastic MDS with aplastic anemia characteristics.
openaire +3 more sources